Strategic Immuno-Monitoring of Patient Therapy
(SIMPATHY)
Working group: Clinical trials.
SIMPATHY: Questions to tackle
Strategic Immuno-Monitoring of Patient Therapy (SIMPATHY) in the context of Basket of Baskets (BoB) trial – Atezolizumab Module.
The crucial questions that SIMPATHY will start to address are:
- How to identify tumours that will respond?
- How to identify why some initially responsive tumours become resistant and how to avoid this or render them responsive again?
- How to transform non-responsive tumours into responsive tumours?
In order to do so the SIMPATHY proposal aims to produce a detailed map of the tumour immune microenvironment before, during and after failure of ICI treatment with the anti-PD-L1 monoclonal atezolizumab, contextualized with genomic and systemic immune features.
This may allow identification of novel biomarkers across cancers of different cell origin. Recent results have shown that pre-treatment analyses may not be sufficient to predict response but that early biopsies on treatment may provide more useful information..
BoB context for SIMPATHY
The context of Basket of Baskets (BoB) for SIMPATHY allows:
- Matched trial-grade clinical data.
- Genomic profiling of all baseline tumour samples with the Cancer Core Europe (CCE) gene panel and whole exome sequencing.
- PBMC, cfDNA analyses.
- Simple integration of further translational assays for SIMPATHY within established infrastructure, with required state-of-the-art assays available across the CCE centers.
- Experience of CCE physicians in obtaining high success rates for baseline and repeat biopsies.
- Bioinformatics expertise shared across CCE centres for data analysis
MEMBERS
7 Renowned European Cancer Centres Collaborate to Advance Cancer Care
Our commitment is to work on advanced cancer research for the benefit of patients
CANCER CORE EUROPE (CCE)